2 August 2024 | AU | Novo Nordisk Launches Wegovy® (Semaglutide) in Australia On 2 August 2024, Australia’s...
Pearce IP BioBlast® for w/e 02 August 2024
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast® for w/e 26 July 2024
26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UCOn 26 July 2024, AbbVie...
Pearce IP BioBlast® for w/e 19 July 2024
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that...
Pearce IP BioBlast for w/e 12 July 2024
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's...
Elanco Sheepish as Patent Application Not Inventive
Elanco Australasia Pty Ltd v Abbey Laboratories Pty Ltd [2024] FCA 640
Pearce IP BioBlast for w/e 05 July 2024
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical...
Pearce IP BioBlast for fortnight ending 28 June 2024
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech...
Pearce IP BioBlast for fortnight ending 14 June 2024
14 June 2024 | AU | Approval Alert: Bayer’s High Dose Eylea® (aflibercept) Approved in Australia On 14 June 2024,...
Pearce IP BioBlast w/e 31 May 2024
31 May 2024 | EU | US | Europe’s CHMP Recommends Dupixent® (Dupilumab) as COPD Add-On Treatment On 31 May 2024,...
Carpark Saga Reaches Finale
SARB Management Group Pty Ltd trading as Database Consultants Australia v Vehicle Monitoring Systems Pty Limited (No 2) [2024] FCAFC 53
Pearce IP BioBlast w/e 24 May 2024
24 MAY 2024 | EU | Shanghai Henlius’ & Organon’s Biosimilar Denosumab Applications Validated by EMA On 24 May...
Pearce IP BioBlast w/e 17 May 2024
17 MAY 2024 | KR | New Indication Alert: MSD’s Keytruda® (Pembrolizumab) Approved in Korea for New NSCLC and Cervical...
Navigating Post-Grant Patent Amendments: Lessons from R F Industries v Mine Site Technologies
R F Industries Pty Ltd v Mine Site Technologies Pty Ltd [2024] APO 16 provides a good example of the usefulness of re-examination and opposition to challenge a granted patent.
Pearce IP BioBlast w/e 10 May 2024
10 MAY 2024 | US | Valorum Biologics to Launch Xbrane and Stada’s Ranibizumab Biosimilar in the US On 10 May 2024,...
Pearce IP BioBlast w/e 03 May 2024
03 MAY 2024 | CA | Lupin & Sandoz Launch Rymti® (etanercept) Biosimilar in Canada On 3 May 2024,...
How’s Your Hamstring?
Vald Pty Ltd sued KangaTech Pty Ltd for patent infringement and Kanga cross-claimed alleging that Vald’s patent is invalid on the basis of lack of support, lack of sufficiency and lack of inventive step.